Amyloidosis Awareness Month exists for a reason.
Not because the disease is new. Not because we lack diagnostic tools. But because, even now, it’s still being missed, often until it’s progressed further than it should.
For a condition that directly impacts cardiac function, accelerates heart failure progression, and now has expanding treatment options, the biggest barrier isn’t access. It’s recognition. And that’s where the gap remains.
What Are We Actually Seeing?
At its core, amyloidosis is a protein-folding disorder. Misfolded proteins accumulate in tissues, disrupting normal function. In the case of transthyretin cardiac amyloidosis (ATTR-CM), those deposits build within the myocardium, leading to restrictive cardiomyopathy and progressive heart failure.
ATTR-CM doesn’t announce itself clearly and overlaps with conditions clinicians manage every day, like heart failure with preserved ejection fraction, hypertensive heart disease, or age-related cardiac changes.
It presents as:
HFpEF that doesn’t respond as expected
Left ventricular wall thickening without a proportional hypertensive history
Cardiac findings that may be accompanied by extracardiac features that don’t fully connect at first glance
A patient presentation that doesn’t fully line up, even when everything “makes sense” on paper
The disease process isn’t subtle, but the presentation often is.
What to Look for Sooner
Improving identification starts with recognizing when a case doesn’t follow the expected path.
That includes cases where:
Heart failure that remains symptomatic despite appropriate management
Left ventricular hypertrophy that seems disproportionate to the patient’s clinical history
Patterns suggesting systemic involvement rather than isolated cardiac disease
From there, guideline-directed evaluation becomes critical:
Targeted imaging approaches that support suspicion
Biomarker assessments that add clarity
Confirmatory testing that moves the diagnosis forward
The shift is subtle but important, moving from treating symptoms to questioning the underlying cause earlier.
The Patients You’re More Likely to Miss
ATTR-CM disproportionately affects African American patients due to the prevalence of the Val122Ile mutation, which significantly increases risk. Despite this, the condition remains underrecognized in this population.
That disconnect reinforces the need for:
Lower thresholds for suspicion in higher-risk populations
More consistent screening in appropriate clinical contexts
Greater awareness of how genetic risk influences presentation
This gap has real consequences—not just in delayed diagnosis, but in delayed access to therapies that can meaningfully alter disease progression.
Why This Matters More Than Ever
The amyloidosis landscape looks very different than it did even a few years ago.
There are now:
Targeted therapies
More defined treatment pathways
Greater clarity around disease progression and management
These advances are only effective if patients are identified early enough to benefit. Delays in diagnosis narrow that window.
How You Can Make a Difference in Practice Right Now
This is where awareness becomes clinical action. Improving outcomes in ATTR-CM starts with earlier recognition, and that starts with clinicians who know when something doesn’t add up.
Staying aligned with how ATTR-CM presents, who is most at risk, and how to move efficiently through diagnostic pathways is critical to closing that gap.
A recent CME activity from CMHC takes a closer look at:
The pathophysiology and clinical presentation of ATTR-CM
The disproportionate burden in African American populations and the role of the Val122Ile mutation
Screening and diagnostic approaches to support earlier identification
Current and emerging treatment strategies
How to select therapies to optimize outcomes across patient populations
It’s not about introducing something new, it’s about sharpening how you recognize what’s already in front of you, earlier.
Deepen your understanding of ATTR-CM, from recognition to treatment decisions, with this complimentary CME activity.
The Bottom Line
Amyloidosis isn’t being missed because it’s invisible.
It’s being missed because it looks familiar enough to pass as something else.
Recognizing that difference earlier doesn’t just improve care, it can directly impact disease progression, preserve cardiac function, and, in many cases, save patients’ lives.
At CMHC, these types of diagnostic challenges are examined through a broader clinical lens—bringing together evolving evidence, patient perspectives, cross-specialty perspectives, and practical strategies that support more confident decision-making in complex cases.
Stay informed on upcoming CMHC programming, agenda updates, and conference workshop opportunities by signing up for event alerts.
